FDA Approved Durvalumab for Limited-Stage Small Cell Lung Cancer

Bishal Tiwari, MD[1]

[1] Nassau University Medical Center, East Meadow, Long Island, NY,USA

Abstract

Limited-stage small-cell lung cancer (LS-SCLC) remains a highly aggressive malignancy with a historically poor prognosis despite advancements in concurrent chemoradiotherapy (cCRT). The introduction of immunotherapy, specifically PD-L1 inhibitors, has transformed treatment strategies by enhancing anti-tumor immune responses. Durvalumab, a fully human monoclonal antibody targeting PD-L1, has demonstrated significant clinical benefit and was recently FDA-approved for LS-SCLC following cCRT. The efficacy of durvalumab was established in the phase III ADRIATIC trial, which enrolled patients with LS-SCLC who achieved disease control post-cCRT. Durvalumab monotherapy significantly improved overall survival (OS) and progression-free survival (PFS) compared to placebo. The median OS for the durvalumab group was 55.9 months, a notable improvement over 33.4 months in the placebo arm (HR: 0.73; $p = 0.0104$). Similarly, PFS was prolonged, underscoring its role as a consolidation therapy.

Durvalumab's safety profile highlights immune-related adverse events, particularly pneumonitis, observed in up to 26% of patients. Risk factors include pre-existing autoimmune conditions, obesity, and lower lung volume spared from radiation. Effective management necessitates early recognition, standardized monitoring protocols, and multidisciplinary collaboration to minimize complications without compromising treatment efficacy. While durvalumab represents a major advancement in LS-SCLC treatment, challenges persist. High recurrence rates and limited clinical trial data for frail and elderly patients emphasize the need for more inclusive research. Future directions include identifying predictive biomarkers and evaluating combination therapies, such as dual checkpoint blockade, to improve outcomes.

In conclusion, durvalumab's approval marks a critical step forward in LS-SCLC management, offering significant survival benefits. Continued research is essential to address existing challenges and optimize therapeutic strategies, ultimately improving long-term outcomes for patients with this aggressive disease.

Key words: SCLC, Durvalumab, survival, response rate

Introduction

Limited-stage small-cell lung cancer (LS-SCLC) presents significant epidemiological and clinical challenges due to its aggressive nature and poor overall prognosis. Approximately 15% of all lung cancer cases are SCLC which primarily affects individuals with a history of smoking[1]. However, only one-third of SCLC cases are diagnosed at this limited stage, where treatment offers the potential for curative outcomes[2]. This highlights importance of early detection measures to

Corresponding Author
Bishal Tiwari, MBBS, Resident Physician, Nassau University Medical Center, East Meadow, Long Island, NY
Email: drbishaltiwari@gmail.com

improve patient outcomes. Even with advances in therapeutic options, the prognosis for LS-SCLC still remains dismal, with only 10–13% of patients with 5-year survival following standard therapy [3] .The disease itself has heterogenous nature which adds further hinders ; genomic and phenotypic variations, including alterations in key genes such as *TP53* and *RB1*, often leading to treatment resistance and influencing outcomes [4,5]. Other prognostic factors like lympho-vascular invasion also play a important role in determining survival outcomes [4].

Advances in immunotherapy, particularly with PD-L1 inhibitors, have advanced cancer treatment horizon by integrating the immune system to combat tumors. These agents particularly target the PD-1/PD-L1 pathway, a crucial mechanism of tumor immune evasion, to restore T-cell function and strengthen anti-tumor activity. By blocking the interaction between PD-L1 and PD-1, these agents enhance T-cell responses, thereby highlighting immune-mediated tumor destruction [6,7].

PD-L1 inhibitors have shown efficacy across various malignancies, including gastrointestinal and urologic cancers, where they have generated improved surgical outcomes and survival benefits [7,8]. Notably, these therapies are crucial even in patients with resistance to conventional treatment strategy, offering a strong alternative with favorable safety profiles [7]. Novel research has also explored the development of small-molecule PD-L1 inhibitors, with proven advantages over monoclonal antibodies. These agents, like the investigational compound X22, demonstrate enhanced tumor penetration and the possibility of oral administration, exhibiting significant preclinical anti-tumor activity[6,9] .

Durvalumab is a fully human monoclonal antibody that targets programmed cell death-ligand 1 (PD-L1), strengthening anti-tumor immune responses by blocking PD-L1's interaction with its receptors. Durvalumab inhibits PD-L1, preventing tumor cells from evading immune detection [10].This mechanism carries a major role in cancer immunotherapy, as it helps to reactivate the immune system against tumor cells. Previously, FDA has approved Durvalumab for various cancers, such as advanced non-small cell lung cancer (NSCLC)[11], extensive-stage small cell lung cancer (ES-SCLC)[10], and biliary tract cancers (BTC)[12], based on significant clinical trial results. Recently on December, 2024 FDA granted Durvalumab approval to limited stage Small Cell Carcinoma [13].It is often used in combination with chemotherapy, improving overall survival rates in patients with advanced cancers [11,12]

While these recent advancements highlight the enormous potential of PD-L1 inhibitors, challenges such as drug resistance and variable patient responses still exist. Continued research is crucial to further diversify their application, overcome limitations and challenges, and improve outcomes across different cancer types. Recent insights into the molecular basis of LS-SCLC have led to the development of targeted therapies, but achieving consistent long-term survival remains difficult. This underlines the crucial need for further research into predictive biomarkers and novel therapeutic strategies to address the challenges in LS-SCLC patients.

Clinical Efficacy

The therapeutic benefits of durvalumab in patients with limited-stage small-cell lung cancer (LS-SCLC) have been evaluated through multiple clinical trials, focusing its use as a consolidation therapy following chemoradiotherapy.The efficacy of durvalumab was evaluated in the ADRIATIC trial (ClinicalTrials.gov identifier

NCT03703297), a randomized, double-blind, placebo-controlled study that involved 730 patients with limited-stage SCLC. Every participants had disease control post concurrent platinum-based chemotherapy and radiation therapy. Patients were randomized into three groups in a 1:1:1 ratio to receive durvalumab as monotherapy, durvalumab in combination with tremelimumab, or placebo.[14]

Overall survival and progression-free survival, the endpoints, were evaluated through blinded independent central review. Durvalumab as a single-agent therapy was associated with a statistically significant improvement in overall survival compared to placebo, with a hazard ratio (HR) of 0.73 (95% CI: 0.57–0.93; p=0.0104). The median OS for patients in the durvalumab group was 55.9 months (95% CI: 37.3 months to not reached), in contrast to 33.4 months (95% CI: 25.5–39.9) in the placebo group.[14]

Durvalumab had enhanced progression-free survival outcomes, with a hazard ratio (HR) of 0.76 (95% CI: 0.61–0.95; p=0.0161). The median PFS in the durvalumab arm was 16.6 months (95% CI: 10.2–28.2), compared to 9.2 months (95% CI: 7.4–12.9) in the placebo arm.[13]

Safety and Tolerability

The prevalence of pneumonitis in patients treated with durvalumab has been significant across different studies, indicating a major concern in clinical practice. Research shows that the incidence of pneumonitis can be influenced by factors such as treatment protocols and patient characteristics. A study showed that in a cohort of 284 patients, 21.5% developed clinically significant pneumonitis, with 2.5% experiencing grade 5 pneumonitis [15].A study involving 189 patients reported a 26% incidence of any grade pneumonitis, with 9% experiencing grade 3 or higher [16]. Another study found a 22.1% incidence of grade 2 or higher pneumonitis in patients receiving durvalumab after chemoradiotherapy, compared to 13.9% in those receiving chemoradiotherapy alone [17].

Factors such as male gender, pre-existing autoimmune conditions, and lower lung volume spared from radiation were significantly linked with higher degree of pneumonitis[16,18].Moreover, obesity was identified as a significant predictor of pneumonitis in one study [15].

Despite the prevalence reported across various studies, the impact of pneumonitis on overall survival remains limited, as some studies found no significant correlation between low-grade pneumonitis and increased mortality [17]. Nevertheless, the variability in incidence rates implies a need for vigilant patient monitoring and management strategies.

The management of immune-related adverse events (irAEs) such as pneumonitis in patients receiving Darvalumab requires a multifaceted approach that takes in account the unique challenges posed by these adverse effects. Optimal treatment strategies involve early recognition, multidisciplinary collaboration, and tailored management protocols that address the specific symptoms and severity of irAEs.

Early Recognition and Monitoring: Timely identification of irAEs is crucial, as delayed treatment can lead to increased morbidity and mortality [19].Institutions should implement standardized monitoring protocols to facilitate early detection and prompt intervention in such cases. [19]

Multidisciplinary Collaboration: Effective management necessitates collaboration among oncologists, rheumatologists, and other specialists to navigate the complexities of irAE treatment [20]. Treatment facilities should develop

institutional protocols that include algorithms for healthcare providers that can have optimal outcomes in case of irAEs [19].

Tailored Treatment Approaches: Current management often depends on corticosteroids; however, alternative immunosuppressive agents may be necessary for steroid-refractory cases [21]. Understanding the underlying mechanisms of irAEs can lead to more targeted therapies that preserve anti-tumor immunity while minimizing adverse effects [22].While these strategies are crucial, the differences in patient responses to treatment and the potential for long-term autoimmune complications underscores the need for ongoing research and refinement of management protocols.

Challenges and Future directions

Durvalumab has emerged as a promising option for the treatment of limited-stage small cell lung cancer (LS-SCLC) following concurrent chemoradiotherapy (cCRT). Despite its potential, several challenges and unmet needs highlights the importance of further research to optimize its clinical application.

Efficacy and Safety Considerations: Clinical trials have demonstrated that durvalumab significantly improves overall survival (OS) and progression-free survival (PFS) compared to placebo in patients with LS-SCLC who exhibit no progression after cCRT [14]. However, modest overall response rates and high recurrence rates indicate the need for advanced predictive biomarkers to help identify patients who are most likely to benefit from this therapy[23].

Limitations in Patient Populations: The exclusion of frail individuals, particularly elderly patients or those with low functional status, from clinical trials limits the application of current findings in broader population group [24]. Considering the therapeutic needs of these underrepresented demographic group is necessary to establish inclusive strategies that can enhance outcomes across diverse population [23].

Future Research Directions: Ongoing investigations are evaluating the efficacy of combining durvalumab with other agents, such as tremelimumab, to augment therapeutic outcomes [14,25]. Moreover research into biomarkers and molecular targets holds promise for improving patient selection and tailoring treatment approaches [23].While durvalumab represents a significant advance in the treatment landscape of LS-SCLC, challenges related to patient selection and the development of predictive tools remain important to its successful integration into clinical practice.

Conclusion

Durvalumab has revolutionized the management of limited-stage small cell lung cancer (LS-SCLC), establishing itself as a cornerstone in treatment paradigms following concurrent chemoradiotherapy (cCRT). Its recent FDA approval for LS-SCLC underscores its clinical efficacy, as evidenced by significant improvements in overall survival and progression-free survival compared to placebo. This milestone represents a critical advancement in addressing the historically poor prognosis of LS-SCLC.

Despite these achievements, the integration of durvalumab into routine clinical practice requires careful consideration of its efficacy, safety profile, and applicability to diverse patient populations. The need for predictive biomarkers remains paramount to refine patient selection and maximize therapeutic benefit. Furthermore, expanding clinical trial eligibility to include frail and elderly patients is essential to ensure equitable access and improve

outcomes for underrepresented groups.

Future research should focus on combination strategies, such as integrating durvalumab with agents like tremelimumab, to enhance efficacy. Investigating molecular targets and novel biomarkers will also facilitate the development of precision approaches tailored to individual patient needs. Collaboration among researchers, clinicians, and regulatory bodies will be pivotal in addressing these challenges and optimizing outcomes.

Durvalumab's approval marks a significant stride forward, but sustained progress hinges on continued innovation and the seamless translation of research findings into clinical practice. A commitment to multidisciplinary efforts will be crucial to overcoming current limitations and improving the long-term prognosis for patients with LS-SCLC.

References:

1. Alam MS, Malik G, Tanwar P, et al. A Review on Small-Cell Lung Cancer: Epidemiology, Pathophysiology, RiskFactors, Diagnosis, Clinical Management and Treatment Modalities. *International Journal of Current Science Research and Review (ijcsrr)*. 6(01):129-151.
2. García-Campelo R, Sullivan I, Arriola E, et al. SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022). *Clinical and Translational Oncology*. 2023/09/01 2023;25(9):2679-2691. doi:10.1007/s12094-023-03216-3
3. Li L, Duan J, Gao Y, et al. Multi-omics predictive model based on clinical, radiomic and genomic features for predicting the response of limited-stage small cell lung cancer to definitive chemoradiotherapy. *Clinical and Translational Medicine*. 2024;14(1):e1522. doi:https://doi.org/10.1002/ctm2.1522
4. Feng J, Wang Y, Yao W, Luo J, Yu K. Comprehensive analysis of prognostic predictors for patients with limited-stage small-cell lung cancer who underwent resection followed by adjuvant chemotherapy. *Annals of Translational Medicine*. 2021;9(14):1169.
5. Zhang L, Zhang Q, Wu Q, et al. Establishment of a prognostic nomogram for elderly patients with limited-stage small cell lung cancer receiving radiotherapy. *Scientific Reports*. 2024/05/25 2024;14(1):11990. doi:10.1038/s41598-024-62533-x
6. Javed SA, Najmi A, Ahsan W, Zoghebi K. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges. Review. *Frontiers in Immunology*. 2024-April-10 2024;15doi:10.3389/fimmu.2024.1383456
7. Han L, Meng Y, Jianguo Z. Research Progress of PD 1/PD L1 Inhibitors in the Treatment of Urological Tumors. *Curr Cancer Drug Targets*. 2024;24(11):1104-1115. doi:10.2174/0115680096278251240108152600
8. Wang D-X, Liu H, Tian J-C, et al. Neoadjuvant immunotherapy based on PD-1/L1 inhibitors for gastrointestinal tumors: a review of the rationale and clinical advances. *International Journal of Surgery*. 2024;110(6):3707-3722. doi:10.1097/js9.0000000000001357
9. Liu L, Zhang H, Hou J, et al. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent In Vivo Anti-tumor Immune Activity. *Journal of Medicinal Chemistry*. 2024/03/28 2024;67(6):4977-4997. doi:10.1021/acs.jmedchem.4c00102
10. Al-Salama ZT. Durvalumab: A Review in Extensive-Stage SCLC. *Targeted Oncology*. 2021/11/01 2021;16(6):857-864. doi:10.1007/s11523-021-00843-0
11. Murakami S. Durvalumab for the treatment of non-small cell lung cancer. *Expert Review of Anticancer Therapy*. 2019/12/02 2019;19(12):1009-1016. doi:10.1080/14737140.2019.1699407
12. Mahipal A, Palmer M, Gile J, Kim R. Durvalumab: A PD-L1 Blocking Antibody for the Treatment of

Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer. *Oncology & Haematology*. 01/01 2023;19:22. doi:10.17925/OHR.2023.19.1.22

13. Administration USFaD. Durvalumab. 12/05/2024 2024;
14. Spigel D, Cheng Y, Cho B, et al. ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). *Journal of Clinical Oncology*. 06/10 2024;42:LBA5-LBA5. doi:10.1200/JCO.2024.42.17_suppl.LBA5
15. Akkad N, Thomas TS, Luo S, Knoche E, Sanfilippo KM, Keller JW. A real-world study of pneumonitis in non-small cell lung cancer patients receiving durvalumab following concurrent chemoradiation. *Journal of Thoracic Disease*. 2023;15(12):6427-6435.
16. Lim CA, Ghosh S, Morrison H, et al. Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study. *Current Oncology*. 2023;30(12):10396-10407.
17. Edwards DM, Sankar K, Alseri A, et al. Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer. *International Journal of Radiation Oncology, Biology, Physics*. 2024;118(4):963-970. doi:10.1016/j.ijrobp.2023.09.050
18. Sato M, Odagiri K, Tabuchi Y, et al. Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. *Cancers*. 2024;16(6):1162.
19. Cheema PK, Iafolla MAJ, Abdel-Qadir H, et al. Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors. *Current Oncology*. 2024;31(10):6356-6383.
20. von Itzstein MS, Gerber DE, Bermas BL, Meara A. Acknowledging and addressing real-world challenges to treating immune-related adverse events. *Journal for ImmunoTherapy of Cancer*. 2024;12(7):e009540. doi:10.1136/jitc-2024-009540
21. Chen YH, Kovács T, Ferdinandy P, Varga ZV. Treatment options for immune-related adverse events associated with immune checkpoint inhibitors. *British Journal of Pharmacology*. n/a(n/a) doi:https://doi.org/10.1111/bph.16405
22. McKenzie J, Sneath E, Trinh A, Nolan M, Spain L. Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities. *Immuno-Oncology and Technology*. 2024;21doi:10.1016/j.iotech.2024.100704
23. Belluomini L, Calvetti L, Inno A, et al. SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs. Review. *Frontiers in Oncology*. 2022-April-14 2022;12doi:10.3389/fonc.2022.840783
24. Gobbini E, Filleron T, Thureau S, et al. 215TiP A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemo-radiotherapy (CRT): DURVALUNG trial. *ESMO Open*. 2024;9doi:10.1016/j.esmoop.2024.102788
25. Cheng Y, Spigel DR, Cho BC, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. *New England Journal of Medicine*. 2024;391(14):1313-1327. doi:doi:10.1056/NEJMoa2404873